Tampere

• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves … Ended recruitment
  2022-502640-12-01 9 2024-09-27 Non-small cell lung cancer (NSCLC)
• An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu … Ended recruitment
  2023-509762-38-00 5 2024-08-01 Respiratory Syncytial Virus Infections
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti … Ended recruitment
  2024-512439-54-01 4 2024-07-24 Non-small cell lung cancer (NSCLC)
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended recruitment
  2022-503004-24-00 5 2023-10-20 Influenza virus
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended recruitment
  2022-500100-21-01 4 2023-09-11 Follicular lymphoma
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended recruitment
  2023-508462-15-00 10 2023-04-27 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended recruitment
  2024-510742-13-00 5 2023-04-19 Pediatric low-grade glioma harboring an activating RAF alteration requ
• PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended recruitment
  2023-505057-40-00 4 2022-12-02 Lung Cancer, Non-Small Cell
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended recruitment
  2023-505579-53-00 5 2022-10-25 Diffuse large B-cell lymphoma (DLBCL)
• A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an … Ended recruitment
  2023-508265-33-00 5 2022-10-13 Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
• Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Boo … Ended recruitment
  2023-510145-25-00 5 2022-08-23 Meningococcal infection
• A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended recruitment
  2023-505255-51-00 5 2022-08-08 Herpes Zoster
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA … Ended recruitment
  2023-506241-30-00 5 2021-11-30 Advanced Colorectal Cancer with KRAS G12C Mutation

Showing 145–168 of 259 trials